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Summary
Background Individuals with a history of recurrent depression have a high risk of repeated depressive relapse or recurrence. 
Maintenance antidepressants for at least 2 years is the current recommended treatment, but many individuals are interested 
in alternatives to medication. Mindfulness-based cognitive therapy (MBCT) has been shown to reduce risk of relapse or 
recurrence compared with usual care, but has not yet been compared with maintenance antidepressant treatment in a 
defi nitive trial. We aimed to see whether MBCT with support to taper or discontinue antidepressant treatment (MBCT-TS) 
was superior to maintenance antidepressants for prevention of depressive relapse or recurrence over 24 months.
Methods In this single-blind, parallel, group randomised controlled trial (PREVENT), we recruited adult patients with 
three or more previous major depressive episodes and on a therapeutic dose of maintenance antidepressants, from 
primary care general practices in urban and rural settings in the UK. Participants were randomly assigned to either 
MBCT-TS or maintenance antidepressants (in a 1:1 ratio) with a computer-generated random number sequence with 
stratifi cation by centre and symptomatic status. Participants were aware of treatment allocation and research assessors 
were masked to treatment allocation. The primary outcome was time to relapse or recurrence of depression, with 
patients followed up at fi ve separate intervals during the 24-month study period. The primary analysis was based on 
the principle of intention to treat. The trial is registered with Current Controlled Trials, ISRCTN26666654.
Findings Between March 23, 2010, and Oct 21, 2011, we assessed 2188 participants for eligibility and recruited 
424 patients from 95 general practices. 212 patients were randomly assigned to MBCT-TS and 212 to maintenance 
antidepressants. The time to relapse or recurrence of depression did not diff er between MBCT-TS and maintenance 
antidepressants over 24 months (hazard ratio 0·89, 95% CI 0·67–1·18; p=0·43), nor did the number of serious 
adverse events. Five adverse events were reported, including two deaths, in each of the MBCT-TS and maintenance 
antidepressants groups. No adverse events were attributable to the interventions or the trial.
Interpretation We found no evidence that MBCT-TS is superior to maintenance antidepressant treatment for the 
prevention of depressive relapse in individuals at risk for depressive relapse or recurrence. Both treatments were associated 
with enduring positive outcomes in terms of relapse or recurrence, residual depressive symptoms, and quality of life.
Funding National Institute for Health Research (NIHR) Health Technology Assessment (HTA) programme, and 
NIHR Collaboration for Leadership in Applied Health Research and Care South West Peninsula.
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Introduction
Depression typically has a relapsing and recurrent course.1 
Without ongoing treatment, individuals with recurrent 
depression have a high risk of repeated depressive relapses 
or recurrences throughout their life with rates of relapse or 
recurrence typically in the range 50–80%.2 Major inroads 
into the substantial health burden attributable to 
depression could be off set through interventions that 
prevent depressive relapse or recurrence in people at 
highest risk. If the factors that make people susceptible to 
depressive relapse or recurrence can be attenuated, the 
recurrent course of depression could potentially be broken.
Currently, most depression is treated in primary care, 
and maintenance antidepressants are the mainstay 
approach for the prevention of relapse or recurrence. The 
UK’s National Institute for Health and Care Excellence 
(NICE) recommends that, to stay well, people with 
a history of recurrent depression should continue 
maintenance antidepressants for at least 2 years.3 
However, adherence rates tend to be poor, maintenance 
antidepressant treatment is only protective for as long as 
it is taken4 and is contraindicated for some groups, and 
many patients express a preference for psychosocial 
interventions that provide long-term protection against 
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relapse or recurrence. Patients at increased risk of relapse 
show less protection from maintenance antidepressants 
than do patients at low risk and many patients express a 
preference for psychosocial interventions that provide 
long-term protection against relapse or recurrence.
Mindfulness-based cognitive therapy (MBCT) was 
developed as a psychosocial intervention for teaching 
people with recurrent depression the skills to stay well in 
the long term.5 A systematic review and meta-analysis6 of 
six randomised controlled trials (n=593) suggests that 
MBCT signifi cantly reduces the rates of depressive relapse 
or recurrence compared with usual care or placebo, 
corresponding to a relative risk reduction of 34% (risk ratio 
0·66, 95% CI 0·53–0·82). Evidence is accumulating that 
MBCT might confer most benefi t to patients at greatest 
risk, for example those reporting childhood adversity.7,8 A 
key remaining uncertainty is whether MBCT provides an 
alternative for people wishing to discontinue 
antidepressants.9 On the basis of our pilot trial,10 we tested 
whether MBCT with support to taper or discontinue 
antidepressant treatment (MBCT-TS) was better than 
maintenance antidepressants in terms of: a primary 
outcome of prevention of depressive relapse or recurrence 
over 24 months; and secondary outcomes of depression-
free days, residual depressive symptoms, psychiatric and 
medical comorbidity, quality of life, and cost-eff ectiveness 
over 24 months.
Method
Study design and participants
PREVENT was a multicentre, pragmatic, single-blind, 
parallel randomised controlled trial examining MBCT-TS 
versus maintenance antidepressants. The study design 
and procedures are presented in full in in the published 
trial protocol.11,12
Participants were recruited from general practices in 
urban and rural settings in four UK centres: Bristol, 
Exeter and east Devon, north and mid Devon, and south 
Devon. Inclusion criteria were a diagnosis of recurrent 
major depressive disorder in full or partial remission 
according to the Diagnostic and Statistical Manual of 
Mental Disorders-IV (DSM-IV); three or more previous 
major depressive episodes; age 18 years or older; and on a 
therapeutic dose of maintenance antidepressant drugs in 
line with the British National Formulary (BNF)13 and 
NICE guidance. Exclusion criteria were a current major 
depressive episode, comorbid diagnoses of current 
substance misuse; organic brain damage; current or past 
psychosis, including bipolar disorder; persistent antisocial 
behaviour; persistent self-injury needing clinical manage-
ment or therapy; and formal concurrent psychotherapy. 
All participants gave written informed consent.
Most participants were identifi ed through searches of 
computerised general practitioner (GP) practice databases 
to identify patients who were currently being prescribed a 
therapeutic dose of antidepressants. PREVENT was also 
advertised locally and interested patients could self-refer. 
GPs had the opportunity to exclude patients they felt 
would be unsuitable and a letter of invitation was sent to 
the remaining identifi ed patients. Patients who expressed 
an interest in the trial were screened over the telephone to 
establish potential eligibility and if suitable were invited 
to attend a baseline interview.
The study was approved by the UK National Health 
Service South West Research Ethics Committee 
(09/H0206/43) and we obtained research governance 
approval from the local primary care trusts or health 
boards. The trial was conducted and reported in 
accordance with CONSORT guidelines.14,15
Randomisation and masking
Participants were randomly allocated (in a 1:1 ratio) to 
receive either maintenance antidepressant treatment or 
an 8-week MBCT class that included support to taper or 
discontinue their maintenance antidepressant medication 
(MBCT-TS).
Patients were randomly assigned to the two groups with a 
computer-generated random number sequence stratifi ed 
according to recruitment centre and partici pants’ symp-
tomatic status at randomisation using the GRID-Hamilton 
Rating Scale for Depression (GRID-HAMD)16 cutoff  of less 
than 8 being asymptomatic and greater than or equal to 8 
being partially symp tomatic.17 Allocation was undertaken 
using a password-protected website maintained by the 
Peninsula Clinical Trials Unit, independent of the trial. The 
trial administrator informed participants of the outcome of 
randomisation via a letter; research assessors remained 
masked to treatment allocation for the duration of the 
follow-up period. The fi delity of this masking was moderate 
with assessors correctly guessing allocation for 56% of 
assessments. In view of the nature of the interventions, 
patients and clinicians were aware of treatment allocation.
Procedures
MBCT is a manualised, group-based skills training 
programme designed to enable patients to learn skills that 
prevent the recurrence of depression.18 It is derived from 
mindfulness-based stress reduction, a programme with 
proven effi  cacy in ameliorating distress in people with 
chronic disease, and cognitive-behavioural therapy for 
acute depression, which has shown effi  cacy in prevention 
of depressive relapse or recurrence. MBCT is intended to 
enable people to learn to become more aware of their bodily 
sensations, thoughts, and feelings associated 
with depressive relapse or recurrence and to relate 
constructively to these experiences. Participants learn 
mindfulness practices and cognitive-behavioural skills both 
in session and through homework assignments. Therapists 
provide support to patients in learning to respond 
adaptively to thoughts, feelings, and experiences that might 
otherwise have triggered depressive relapse. The 
programme consists of eight 2·25 h group sessions, 
normally over consecutive weeks, with four refresher 
sessions off ered roughly every 3 months for the following 
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year. Four therapists delivered 21 MBCT-TS groups in 
various settings including research clinical facilities, 
hospital sites, and the community.
Before therapists progressed to running trial groups, an 
independent check on their competency was established. 
An experienced MBCT therapist independent of the trial 
rated at least two videotapes for every potential therapist 
using the Mindfulness-Based Interventions Teacher 
Assessment Criteria19 and MBCT Adherence Scale 
(MBCT-AS).20 She made an overall judgment as to whether 
the therapists were competent and adhered to the MBCT 
manual, and therapists only progressed once competency 
in all domains was clearly established. During the trial, the 
same rater assessed two sessions from each of the 
21 MBCT-TS courses using the MBCT-AS, which indicated 
that the MBCT teaching was at required competency or 
adherence levels and above. The sessions second rated 
were randomly selected by the trial team before the start of 
the intervention, and therapists were unaware which of 
their sessions would be assessed. During the trial, 
therapists received group supervision every 2 weeks for 3 h.
Patients in the MBCT-TS group received support to 
taper or discontinue their maintenance antidepressants 
both from the MBCT-TS therapist and their GPs. The 
study team provided guideline information to GPs and 
patients about typical tapering or discontinuation 
regimens and possible withdrawal eff ects. The guidelines 
recommended that patients began a tapering regimen 
after 6 weeks of treatment; however, GPs and patients 
determined the tapering or discontinuation regimen. 
Letters signed by the chief investigator and trial GP (RB) 
were sent to patients’ GPs and copied to the patient, 
prompting the GP to have a discussion with the patient 
about a suitable tapering or discontinuation regimen 
after 4–5 weeks of the MBCT-TS group sessions. At the 
end of the eight MBCT-TS sessions, another letter 
was sent reminding the GP to ensure a tapering or 
discontinuation regimen was in place.
Patients in the maintenance antidepressant group 
received support from their GPs to maintain a therapeutic 
level of antidepressant medication in line with BNF13 and 
NICE guidelines for the 2-year follow-up period.
As described fully in the trial protocol,11,12 we encouraged 
all participants to adhere to medication for the full length 
of the trial by writing to all trial participants and their 
GPs after every follow-up reminding them that the trial 
was seeking to compare staying on antidepressants for 
2 years with taking part in mindfulness classes and 
tapering or discontinuation of antidepressant treatment. 
However, patients remained in the trial whatever 
treatment choices they made.
Participants were assessed at six timepoints: baseline 
(before randomisation), 1 month after the end of the 
8-week MBCT-TS programme (or the equivalent time in 
the maintenance antidepressant group), which varied 
between 12 and 24 weeks post-randomisation, and at 
9, 12, 18, and 24 months post-randomisation.
Outcomes
The primary outcome measure was time to relapse or 
recurrence of depression, with patients followed up at 
fi ve separate intervals during the 24-month period of 
study. We assessed the time between assessments 
retrospectively according to the depression module of 
the Structured Clinical Interview for DSM–IV (SCID).21 
We defi ned relapse or recurrence as an episode meeting 
DSM-IV criteria for a major depressive episode.11,21
The secondary outcomes were number of depression-
free days, residual depressive symptoms, psychiatric and 
medical comorbidity, quality of life, and cost-eff ectiveness. 
At each follow-up we recorded the number of depression-
free days based on episode duration as assessed by the 
SCID, residual depressive symptoms as assessed by the 
GRID-HAMD22 and the 21-item self-report Beck 
Depression Inventory (BDI),23 psychiatric comorbidity 
using the relevant SCID modules and medical 
comorbidities using the Medical Symptom Checklist 
(MSCL), quality of life using the WHO Quality of Life 
instrument (WHOQOL-BREF),24 and health-related quality 
of life using the EQ-5D-3L (three level version).25,26
The economic perspective included all hospital and 
community health and social services, plus productivity 
losses, known to be a substantial cost in depression.27 We 
obtained MBCT group data from therapist records. We 
obtained data on indirect time related to MBCT delivery, 
including preparation and supervision, from trial 
therapists. We obtained data on drugs and use of all other 
services using the Adult Service Use Schedule (AD-SUS) at 
each follow-up, modifi ed and successfully used in our 
previous MBCT trial.10 We confi rmed ADM prescriptions 
and GP contacts via GP records. We measured productivity 
losses as a result of time off  work or reduced productivity at 
work due to illness using the absenteeism and presenteeism 
questions of the WHO’s Health and Work Performance 
Questionnaire (HPQ).28
All unit costs were for the fi nancial year 2011–12, and 
costs and quality-adjusted life-years (QALYs) incurred in 
the second year were discounted by 3·5% as recommended 
by NICE.29 We calculated the cost of MBCT-TS directly from 
salaries using a micro-costing approach used in our 
previous trial.10 We applied national UK unit costs to 
medication and all other health and social services. We 
calculated productivity losses using the friction cost 
approach for absenteeism30 and using the method set out 
by Kessler and colleagues28 for presenteeism. The appendix 
shows full details of all unit costs.
At an early Trial Management Group Meeting we 
decided on the fi nal list of measures to assess these 
constructs, and the WHOQOL was selected as secondary 
outcome measure quality of life (Aug 19, 2009). An 
oversight meant that this change was not included in the 
published protocol or in the ISRCTN register 
(ISRCTN26666654), although the full list of primary and 
secondary outcomes were logged at the fi rst Trial Steering 
Committee (Dec 1, 2009) and in the CONSORT diagram 
See Online for appendix
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Figure 1: Trial profi le
GP=general practitioner. 
MBCT-TS=mindfulness-based 
cognitive therapy with support 
to taper or discontinue 
antidepressant medication. 
28 597 participants identified on search
19 608 invites sent
2188 assessed for eligibility 
8989 GP excluded
424 randomised
17 lost to follow-up
9 withdrew
20 lost to follow-up
8 withdrew
 1881 declined further contact
 14 756 no response
 872 could not contact back
212 assigned to MBCT-TS
 176 completed 4 or more sessions
 30 initiated treatment but attended less than 4 sessions
 6 did not initiate treatment 
184 completed MBCT+ 1 follow-up186 completed MBCT+ 1 follow-up
212 assigned to maintenance antidepressant medication
 162 remained on a BNF therapeutic dose of 
  antidepressant medication
 50 did not remain on a BNF therapeutic dose of 
  antidepressant medication
23 lost to follow-up
11 withdrew
32 lost to follow-up
10 withdrew
176 completed 9-month follow-up178 completed 9-month follow-up
15 lost to follow-up
13 withdrew
20 lost to follow-up
15 withdrew
2 died
10 lost to follow-up
17 withdrew
2 died
18 lost to follow-up
11 withdrew
183 completed 12-month follow-up184 completed 12-month follow-up
20 lost to follow-up
16 withdrew
1 died
175 completed 18-month follow-up175 completed 18-month follow-up
10 lost to follow-up
17 withdrew
2 died
183 completed 24-month follow-up183 completed 24-month follow-up
212 included in the intention-to-treat population212 included in the intention-to-treat population
1764 excluded 
1120 not eligible
644 declined
89 self-referred
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reported in the Data Monitoring Committee (DMC) 
charter (dated May 24, 2010), which was signed by all 
DMC members. There is therefore a discrepancy between 
the published protocol that does not list the WHOQOL as 
a secondary outcome (Kuyken et al, 2010) and this 
outcome paper, which does report it. This discrepancy has 
no impact on the interpretation of the fi ndings.
Statistical analysis
The study was powered to detect a hazard ratio of 0·6310 
between the two treatments at 24 months for the primary 
outcome, with 90% power, two-sided 5% α level, assuming 
a small clustering eff ect (intraclass correlation=0·01) and 
allowing for 20% loss to follow-up, producing a target 
sample size of 420 (210 per group). All analyses were 
prespecifi ed in a detailed statistical analysis plan that was 
reviewed by the independent Trial Data Monitoring and 
Steering Committees. Analyses were undertaken according 
to the intention-to-treat principle except where stated.
The primary analysis was a between group comparison 
of time to relapse or recurrence at 24 months using a 
Cox regression proportional hazards model adjusted for 
stratifi cation variables. We did two predefi ned secondary 
analyses of the primary outcome comparing groups 
according to whether participants had received an adequate 
dose of treatment and adhered to treatment as invited. We 
defi ned an adequate dose of treatment for MBCT-TS as 
attending four or more group sessions and for maintenance 
antidepressants as a BNF therapeutic dose of 
antidepressants during the 24-month follow-up period. We 
defi ned adherence to treatment as invited for MBCT-TS as 
attending four or more classes and at some point 
discontinuing or reducing antidepressants; for 
maintenance antidepressants, we defi ned adherence as a 
BNF therapeutic dose throughout the 24-month follow-up.
We compared secondary outcomes across all timepoints 
using repeated measures mixed regression models. 
Missing data were assumed missing at random and 
sensitivity analysis examined the eff ect of missing data 
using multiple imputations.31 We report between group 
inference for secondary outcome analyses based on 
complete case and imputed datasets.
We used interaction terms to undertake predefi ned 
exploratory subgroup analyses on the primary outcome, 
across the stratifi cation variables (recruitment centre and 
baseline depression severity) and reported childhood 
abuse.12,32 Participants in the high abuse group reported 
experiencing childhood physical or sexual abuse or scored 
above the median score for the Measure of Parenting 
Scale (MOPS)33 abuse subscale. Participants completed 
the MOPS at baseline as part of an embedded process-
outcome study.11 The abuse subscale asks participants to 
indicate how true they felt certain statements about their 
parents’ behaviour were: for example, “parent was 
physically violent or abusive of me; parent made me feel 
unsafe”. Participants in the low reported childhood abuse 
group scored below the median score for the MOPS abuse 
MBCT-TS (n=212) m-ADM (n=212)
Demographic characteristics
Women 151 (71%) 174 (82%)
White ethnic origin 210 (99%) 210 (99%)
Age, years
Mean (SD) 50 (12) 49 (13)
Range 22–78 20–79
Marital status
Single 42 (20%) 38 (18%)
Married, cohabiting, or civil partnership 125 (59%) 140 (66%)
Separated, divorced, or widowed 44 (21%) 33 (16%)
Missing 1 (<1%) 1 (<1%)
Education
No educational qualifi cation 10 (5%) 10 (5%)
O levels or GCSEs 36 (17%) 45 (21%)
AS and A levels or vocational qualifi cation 84 (40%) 92 (43%)
University training 77 (36%) 61 (29%)
Missing 5 (2%) 4 (2%)
Religion
Christian 133 (63%) 139 (66%)
Other 10 (5%) 4 (2%)
None 68 (32%) 68 (32%)
Missing 1 (<1%) 1 (<1%)
Salary (£)
Mean (SD) £19 930 (13 387) £18 024 (13 582)
Range £1200–£72 000 £792–£80 000
Social class
Class 0 96 (45%) 76 (36%)
Class 1 53 (25%) 52 (25%)
Class 2 22 (10%) 38 (18%)
Class 3 5 (2%) 6 (3%)
Class 4 0 2 (1%)
Class 5 35 (17%) 37 (17%)
Not classifi ed 1 (<1%) 1 (<1%)
Stratifi cation variables
Depressive symptomology at randomisation
Asymptomatic 163 (77%) 162 (76%)
Symptomatic 49 (23%) 50 (24%)
Recruitment site
Bristol 33 (16%) 31 (15%)
Exeter and east Devon 72 (34%) 76 (36%)
North and mid-Devon 55 (26%) 54 (25%)
South Devon 52 (25%) 51 (24%)
Psychiatric characteristics
Current depressive symptomology GRID-HAMD 4·8 (4·3) 4·6 (4·3)
Current depressive symptomology BDI-II score 13·8 (10·2) 14·5 (10·1)
Previous major depressive episodes
<6 episodes 120 (57%) 106 (50%)
≥6 episodes 92 (43%) 106 (50%)
Age (years) at fi rst depression onset 24·4 (11·5) 25·4 (13·3)
Time (months) since last depressive episode 21·2 (27·0) 17·1 (23·0)
Number of comorbid DSM-IV axis I psychiatric 
diagnoses
0·5 (0·9) 0·7 (0·9)
(Table 1 continues on next page)
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subscale and did not report childhood physical or sexual 
abuse.
We analysed diff erences in mean costs using standard 
parametric t tests with the validity of results confi rmed 
using bias-corrected, non-parametric bootstrapping 
(repeat re-sampling).34,35 The primary economic analysis 
compared MBCT-TS and maintenance antidepressant 
treatment from the health and social care perspective 
preferred by NICE;29 secondary analyses included 
productivity losses. Cost-eff ectiveness was explored using 
the net benefi t approach36 with eff ectiveness measured in 
terms of the primary outcome measure (depressive relapse 
or recurrence) and QALYs calculated with the EQ-5D. 
Uncertainty around the cost and eff ectiveness estimates 
was represented by cost-eff ectiveness acceptability curves.37 
All analyses were undertaken using Stata v.13.38
Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, interpretation of data, or writing 
of the paper. The corresponding author had full access to 
all the data in the study and had fi nal responsibility for 
the decision to submit for publication.
Results
Between March 23, 2010, and Oct 21, 2011, of 
2188 participants assessed for eligibility, we recruited 
424 patients from 95 general practices. Of these, 
212 participants were allocated to receive MBCT-TS 
and 212 participants to maintenance antidepressant 
treatment (fi gure 1). Primary outcome data were obtained 
for 189 (89%) participants in the MBCT-TS group and 
194 (92%) participants in the maintenance 
antidepressants group; the remaining participants’ data 
were censored at their last follow-up. We retained 
366 (86%) of 424 participants over the 24-month follow-up 
period. At 24 months, we obtained secondary outcome 
data for 173 (82%) participants in the MBCT-TS group 
and for 175 (83%) in the maintenance anti depressants 
group. The pattern of collected secondary outcomes was 
similar for each group throughout the whole follow-up 
period, 84% MBCT-TS and 83% maintenance 
antidepressants. The data available for analysis were 
comfortably within the margin required by the power 
calculation.
Baseline characteristics were balanced between the 
two groups with the possible exception of gender (table 1). 
Because no evidence exists that patients’ gender moderates 
MBCT treatment outcome,10 we did not add gender in the 
primary analysis model. Table 2 shows treatment adherence 
and the extent to which patients followed invitations to 
discontinue maintenance antidepressants; more than 75% 
of patients adhered to treatment as intended.
We observed little or no clustering in primary or 
secondary outcomes by therapist. Because model results 
accounting for clustering by therapist were identical to 
those obtained for the primary intention-to-treat analysis, 
we report outcome fi ndings without consideration of 
therapist clustering.
Primary analysis of the primary outcome showed no 
evidence of a reduction in the hazard of relapse or 
recurrence with MBCT-TS compared with maintenance 
antidepressant treatment in the intention-to-treat 
analysis (hazard ratio [HR] 0·89, 95% CI 0·67–1·18, 
p=0·43), with 94 (44%) of 212 patients in the MBCT-TS 
group relapsing compared with 100 (47%) of 212 in 
MBCT-TS (n=212) m-ADM (n=212)
(Continued from previous page)
Received outpatient psychiatric or psychological 
treatment
103 (49%) 108 (51%)
Attempted suicide 48 (23%) 53 (25%)
Number of previous attempts 1·7 (1·1) 1·9 (1·5)
Severity of reported childhood abuse
High 105 (50%) 111 (52%)
Low 105 (50%) 101 (48%)
Missing 2 (1%) 0
Quality of life
How would you rate your quality of life? 3·7 (0·8) 3·7 (0·8)
How satisfi ed are you with your health? 2·9 (1·0) 3·1 (1·0)
Physical 14·5 (6·5) 14·4 (5·1)
Psychological 12·6 (2·6) 12·3 (2·6)
Social 13·4 (3·4) 13·1 (3·4)
Environment 15·0 (2·4) 15·1 (2·6)
Health-related quality of life (EQ-5D tariff s) 0·760 (0·268) 0·778 (0·211)
Data are number of participants (%) or mean (SD), unless otherwise specifi ed. Quality of life assessed using the WHO 
quality of life assessment with higher scores indicating a higher quality of life. MBCT-TS=mindfulness-based cognitive 
therapy with support to taper or discontinue antidepressant medication. m-ADM=maintenance antidepressant 
medication. GCSE=general certifi cate of secondary education. GRID-HAMD=Hamilton Rating Scale for Depression set out 
in a grid. BDI-II=Beck Depression Inventory-II. DSM-IV=Diagnostic and Statistical Manual of Mental Disorders, 4th Edn.
Table 1: Baseline characteristics of participants for the intention-to-treat population 
Number of patients 
(%)
m-ADM treatment adherence
Remained on therapeutic dose 162 (76%)
Did not remain on therapeutic dose 50 (24%)
MBCT-TS treatment adherence
Participants who did not initiate MBCT treatment 6 (3%)
Participants who initiated MBCT treatment 206 (97%)
Mean number of sessions attended 6
Mode number of sessions attended 8
Standard deviation sessions attended 2·4
Completed four or more MBCT sessions 176 (83%)
ADM use in patients who attended four or more sessions of MBCT-TS
No reduction to their ADM dose 23 (13%)
Reduced their ADM 29 (17%)
Discontinued their ADM 124 (71%)
m-ADM=maintenance antidepressant medication. MBCT-TS=mindfulness-based 
cognitive therapy with support to taper or discontinue antidepressants.
Table 2: Adherence to treatment in each trial group 
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the maintenance antidepressants group, log-rank 
c² (1)=0·67, p=0·41 (fi gure 2).
Another assessor rated every fi rst actual or borderline 
relapse or recurrence and we recorded 90% agreement 
between the raters (κ=0·62, 95% CI 0·48–0·77, p<0·0001). 
A subset of 112 SCID interviews were also second rated by 
an experienced rater who was independent of the trial with 
96% agreement being recorded (κ=0·90, 0·82–0·98, 
p<0·0001).
Secondary analyses on our primary outcome exploring 
the eff ect of adherence to treatment showed a non-
signifi cant reduction in the hazard of relapse or recurrence 
with MBCT-TS compared with maintenance antidepressant 
treatment at 24 months in participants who received an 
adequate dose of treatment (HR 0·79, 95% CI 0·58–1·08, 
p=0·14), with 81 (46%) of 176 patients in the MBCT-TS 
group relapsing compared with 80 (49%) of 162 in the 
maintenance antidepressants group, log-rank c²(1)=2·3, 
p=0·13 (appendix). There was a non-signifi cant reduction 
in the hazard of relapse or recurrence with MBCT-TS 
compared with maintenance antidepressant treatment at 
24 months in participants who followed the invited 
treatment with respect to use of antidepressants (HR 0·77, 
0·56–1·06, p=0·10), with 70 (46%) of 153 patients in the 
MBCT-TS relapsing compared with 80 (49%) of 162 in the 
maintenance antidepressants group, log-rank c²(1)=2·7, 
p=0·10 (appendix). In view of their non-randomised 
nature, these secondary analyses are prone to selection 
bias and confounding (appendix).
We did not note a diff erence in treatment eff ect on the 
primary outcome across either stratifi cation variable 
subgroup of depression severity at baseline or centre 
(table 3). However, we noted a signifi cant interaction 
between severity of reported childhood abuse and 
treatment group. Specifi cally, compared with maintenance 
antidepressant treatment, MBCT-TS reduced the risk of 
relapse or recurrence for participants with high severity of 
reported childhood abuse (49 [47%] of 105 vs 65 [59%] of 111) 
whereas there was a slightly higher risk of relapse with 
MBCT-TS in the low severity of childhood abuse subgroup 
(44 [42%] of 105 vs 35 [35%] of 101) compared with the 
maintenance antidepressants group (table 3). We noted 
several diff erences in the baseline characteristics of 
participants with high and low severity of reported 
childhood abuse. Individuals who reported a more abusive 
childhood had had more previous psychiatric treatments 
including more hospital admissions, had had more 
previous episodes of depression and made more suicide 
attempts, had a greater chance of a family history of both 
suicide and mental illness, and were more likely to smoke 
than were participants who reported a less abusive 
childhood (appendix).
With respect to our secondary outcomes, we noted no 
evidence of the superiority of MBCT-TS over main-
tenance antidepressants (table 4). Furthermore, none of 
the secondary outcome treatment eff ects at any follow-up 
points exceeded a standardised mean diff erence of 0·4.
MBCT-TS group attendance was estimated to cost 
£112 per participant (table 5). Use of other health-care and 
social care services diff ered little between groups 
(appendix) and hence total health and social care cost per 
participant did not diff er signifi cantly between the MBCT-
TS and the maintenance antidepressants group (mean 
diff erence £124, 95% CI –749·98 to 972·57, p=0·80). 
Results including patient costs (productivity losses and out 
of pocket expenditure) were also non-signifi cant (table 5).
Cost-eff ectiveness analysis (appendix) suggests a 
trade-off  between MBCT-TS and maintenance anti-
depressants when eff ects are measured in terms of relapse 
(costs higher and outcomes better), implying improve-
MBCT-TS Maintenance 
antidepressants
Stratifi ed HR 
(95% CI)
Interaction HR (95% CI); 
p value
Depression severity
Asymptomatic 
(HRSD <8)*
163 (77%) 162 (76%) 0·83 (0·60–1·15)
Symptomatic 
(HSRD ≥8)
49 (23%) 50 (24%) 1·06 (0·62–1·18) 1·27 (0·68–2·39); 0·46
Centre
South Devon* 52 (25%) 52 (24%) 0·61 (0·33–1·13)
Bristol 33 (16%) 31 (15%) 1·60 (0·54–2·12) 1·75 (0·70–4·39)
Exeter and east 
Devon
72 (34%) 76 (36%) 1·10 (0·68–1·81) 1·81 (0·83–3·96)
North and 
mid-Devon
55 (26%) 54 (25%) 0·84 (0·49–1·43) 1·37 (0·61–3·08); 0·47†
Childhood abuse
Lower risk* 105 (50%) 101 (48%) 1·31 (0·83–2·04)
Higher risk 105 (50%) 111 (52%) 0·69 (0·47–1·00) 0·53 (0·29–0·95); 0·03
Data are number of participants (%) unless otherwise stated. HR=hazard ratio. HRSD=Hamilton Rating Scale for 
Depression. MBCT-TS=mindfulness-based cognitive therapy with support to taper or discontinue antidepressants. 
*Reference subgroup. †p value for treatment-centre interaction across centres. 
Table 3: Subgroup analyses of treatment eff ect on days to relapse 
Figure 2: Survival curves (of not relapse or recurrence) over a 24-month follow-up period for the 
intention-to-treat population
m-ADM=maintenance antidepressant medication. MBCT-TS=mindfulness-based cognitive therapy with support 
to taper or discontinue antidepressant medication.
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Baseline MBCT + 1 month 9 months 12 months 18 months 24 months p value* p value†
Mean (SD) N Mean (SD) N Mean (SD) N Mean (SD) N Mean (SD) N Mean (SD) N
Depression
Depression-free days 0·66 0·63
m-ADM ·· ·· ·· ·· ·· ·· ·· ·· ·· ·· 607·4 
(196·4)
212
MBCT-TS ·· ·· ·· ·· ·· ·· ·· ·· ·· ·· 607·4 
(203·7)
212
Residual depressive symptoms
BDI 0·18 0·21
m-ADM 14·4 (10·1) 206 13·9 (10·9) 174 10·5 (9·7) 142 11·3 (9·2) 157 11·3 (10·7) 149 11·9 (10·7) 167
MBCT-TS 13·8 (12·4) 210 9·9 (9·7) 174 11·0 (10·5) 151 10·7 (10·0) 167 11·7 (10·6) 142 11·6 (10·9) 169
GRID-HAMD 0·76 0·55
m-ADM 4·6 (4·3) 212 7·4 (6·3) 183 5·6 (6·4) 175 4·7 (5·2) 181 5·3 (6·1) 174 4·7 (5·7) 183
MBCT-TS 4·8 (4·3) 212 6·3 (5·6) 186 6·0 (5·5) 177 5·7 (5·7) 184 5·7 (5·7) 174 4·7 (4·8) 183
Psychiatric and medical comorbidity
Psychiatric comorbidities 0·91 0·90
m-ADM 0·7 (1·0) 212 ·· ·· ·· ·· 0·1 (0·4) 196 ·· ·· 0·3 (0·6) 183
MBCT-TS 0·5 (0·9) 212 ·· ·· ·· ·· 0·1 (0·3) 196 ·· ·· 0·3 (0·7) 183
MSCL 0·42 0·43
m-ADM 21·7 (13·8) 206 ·· ·· ·· ·· 19·3 (13·7) 156 ·· ·· 21·7 (16·3) 167
MBCT-TS 22·8 (14·0) 210 ·· ·· ·· ·· 21·0 (14·0) 167 ·· ·· 22·2 (14·6) 169
Quality of life
WHO-QoL: Q1—overall 
perception of quality of life
0·07 0·03
m-ADM 3·7 (0·8) 205 3·8 (0·9) 173 3·9 (0·8) 141 3·9 (0·9) 157 3·9 (0·9) 149 3·8 (1·0) 167
MBCT-TS 3·7 (0·8) 209 3·8 (0·8) 174 3·7 (0·9) 151 3·7 (0·9) 166 3·7 (0·9) 141 3·7 (0·9) 169
WHO-QoL: Q2—overall 
perception of health
0·97 0·90
m-ADM 3·1 (1·0) 205 3·2 (1·0) 173 3·2 (1·0) 141 3·3 (1·0) 157 3·3 (1·1) 149 3·2 (1·0) 167
MBCT-TS 2·9 (1·0) 209 3·1 (1·0) 174 3·1 (1·1) 151 3·2 (1·1) 166 3·2 (1·0) 141 3·1 (1·0) 169
WHO-QoL physical health 
domain
0·07 0·02
m-ADM 12·3 (2·6) 205 14·3 (3·0) 173 14·8 (3·2) 141 14·7 (3·3) 157 14·7 (3·3) 149 14·9 (5·5) 167
MBCT-TS 12·6 (2·6) 209 14·3 (3·3) 174 14·2 (3·3) 151 14·1 (3·4) 166 13·9 (3·5) 141 13·9 (3·5) 169
WHO-QoL psychological 
domain
0·55 0·68
m-ADM 12·3 (2·6) 205 12·6 (2·8) 173 13·4 (2·7) 141 13·3 (2·7) 157 13·3 (3·0) 149 13·1 (3·0) 167
MBCT-TS 12·6 (2·6) 209 13·4 (2·6) 174 13·3 (3·0) 151 13·3 (2·9) 166 12·9 (2·8) 141 13·1 (2·9) 169
WHO-QoL social relationships 
domain
0·96 0·81
m-ADM 13·1 (3·4) 205 13·3 (3·4) 173 14·0 (3·4) 141 14·2 (3·3) 157 14·2 (3·4) 148 13·9 (3·5) 167
MBCT-TS 13·4 (3·4) 209 13·8 (2·9) 174 13·7 (3·4) 151 13·9 (3·5) 166 14·0 (3·4) 141 13·7 (3·3) 169
WHO-QoL environment domain 0·14 0·04
m-ADM 15·1 (2·6) 205 15·3 (2·5) 173 15·7 (2·3) 141 15·6 (2·6) 157 15·7 (2·6) 149 15·7 (2·7) 167
MBCT-TS 15·0 (2·4) 209 15·21 (2·4) 174 15·4 (2·6) 151 15·2 (2·6) 166 15·3 (2·6) 141 14·9 (2·6) 169
EQ-5D tariff 0·13 0·07
m-ADM 0·778
(0·211)
202 0·760
(0·226)
173 0·773
(0·234)
142 0·764
(0·248)
156 0·768
(0·243)
149 0·757
(0·266)
166
MBCT-TS 0·760
(0·268)
209 0·727
(0·295)
174 0·735
(0·256)
151 0·721
(0·293)
167 0·723
(0·282)
142 0·715
(0·310)
169
m-ADM=maintenance antidepressant medication. MBCT-TS=mindfulness-based cognitive therapy with support to taper or discontinue antidepressant medication. BDI=Beck Depression Inventory. 
GRID-HAMD=GRID Hamilton Rating Scale for Depression. MSCL=medical symptom checklist. WHO-QoL=WHO Quality of Life. *p values reported are the treatment group-time interaction contrasts of marginal 
linear predictions for observed data. †p values reported are the treatment group-time interaction contrasts of marginal linear predictions for including imputed data. All models adjusted for baseline depression 
severity category on Hamilton scale and centre.
Table 4: Intention-to-treat repeated measures amalyses at 1 month after treatment, and follow-up at 9, 12, 18, and 24 months for secondary outcomes 
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ments in the percentage of participants who relapse can 
only be gained with additional expenditure. In terms of 
QALYs, MBCT-TS is dominated by maintenance 
antidepressant treatment (MBCT-TS costs higher and 
outcomes poorer, on average, than maintenance 
antidepressant treatment). Irrespective of measure of 
eff ect, exploration of statistical uncertainty suggests that 
the probability of MBCT-TS being more cost eff ective than 
maintenance antidepressants does not rise above 52%.
Serious adverse events were monitored and a total of ten 
serious adverse events were reported, four of which 
resulted in the death of the participant. These adverse 
events were evenly split between the two trial groups 
(three non-fatal and two fatal serious adverse events in 
each group) and reported to the Trial Steering and Data 
Monitoring Committees who concluded that there was no 
reason to believe that any of the serious adverse events 
were related to either the intervention or the trial. 
Discussion
We noted no evidence for the superiority of MBCT-TS 
compared with maintenance antidepressants for patients 
with recurrent depression in terms of the primary outcome 
of time to depressive relapse or recurrence over 24 months 
or any of the secondary outcomes. Cost-eff ectiveness 
analysis does not support the hypothesis that MBCT-TS is 
more cost eff ective than maintenance antidepressants, in 
terms of either relapse or recurrence or QALYs.
Before this study, only two small studies10,39 had 
compared MBCT-TS with maintenance antidepressants 
(panel). In our pilot trial,10 MBCT-TS (n=62) was 
compared with maintenance antidepressant treatment 
(n=61) over a 15-month follow-up, and relapse or 
recurrence rates were 47% for MBCT-TS, compared with 
60% for maintenance antidepressants.10 In the second 
study,39 84 patients with recurrent depression who had 
remitted on antidepressants were randomly assigned to 
MBCT-TS, maintenance antidepressants, or pill placebo. 
Relapse or recurrence rates noted over 18 months of 
follow-up did not diff er for MBCT-TS (28%, n=5/18) and 
maintenance antidepressants (27%, n=3/11), but both 
were lower than with placebo (71%, n=10/14).39
Relapse or recurrence rates in people with three or 
more previous episodes are as high as 80% over 2 years.2 
Moreover, results from meta-analyses consistently 
suggest that maintenance antidepressant treatment 
reduces the odds of relapse by two-thirds or a halving of 
absolute risk compared with usual care or placebo.4 
Future research should therefore examine the hypothesis 
that MBCT-TS would provide benefi ts over and above 
either usual care, no treatment, or pill placebo.
Across both treatment groups, outcomes were 
comparatively good over the 2 years of follow-up in terms 
of relapse or recurrence, residual symptoms, and quality 
of life (table 4).
Consistent with an emergent pattern of fi ndings,7 MBCT 
might confer most benefi t to patients at greatest risk of 
relapse. A randomised trial7 of patients with a history of 
three or more episodes of depression (n=274) compared 
MBCT, psycho-education, and usual care over a 12-month 
follow-up. MBCT provided signifi cant protection against 
relapse or recurrence for participants with increased risk 
due to history of childhood abuse, but showed no signifi cant 
advantage over the whole group.7 Findings from trials of 
psychosocial approaches have shown that more intensive 
psychosocial treatments confer protection for those most at 
risk. For example, in a two-arm randomised trial over a 
21-month follow-up, relapse or recurrence rates were 51% 
for maintenance cognitive behavioural therapy (CBT) and 
60% for psycho-education, but in those at greatest risk, 
CBT conferred greater protection than did 
psycho-education.40 A reported history of abuse and 
adversity is associated with worse outcomes in people who 
have depression.41 Perhaps MBCT confers resilience in this 
group at highest risk because patients learn skills that 
address some of the underlying mechanisms of relapse or 
recurrence, a question we will explore in a subsequent 
publication from this trial. Studies are needed that have the 
primary aim of establishing the eff ectiveness and 
mechanism of MBCT for those at diff ering levels of risk of 
relapse, with robust measures of risk.
This largest trial of any mindfulness-based approach to 
date answered an important clinical question of high 
relevance to GPs and patients at risk for depressive relapse 
MBCT-TS (n=181) Maintenance 
antidepressants (n=180)
Mean diff erence (95% CI)* p value*
MBCT 112·00 (0·00) 0·00 (0·00)
Antidepressants 40·10 (72·13) 69·79 (168·48)
Hospital and community services 2332·43 (4065·88) 2290·62 (4190·65)
Total health-care PSS 2484·52 (4077·31) 2360·41 (4205·58) 124·11 (–749·98 to 972·57) 0·800
Out of pocket costs to patients 56·76 (168·29) 83·33 (283·12)
Productivity losses (n=265) 504·26 (1881·49) 310·54 (761·06)
Societal costs (n=252) 3204·05 (4011·91) 2754·92 (4465·07) 449·14 (–842·18 to 1286·26) 0·681
Data are mean (SD) unless otherwise stated. MBCT-TS=mindfulness-based cognitive therapy with support to taper or discontinue antidepressant medication. 
MBCT=mindfulness-based cognitive therapy. PSS=personal social services. *Adjusted for stratifi cation variables.
Table 5: Mean cost per participant over the 24-month follow-up period (£)
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or recurrence. The internal validity of the trial was 
established through the fi delity of MBCT-TS delivery, high 
rates of treatment adherence, excellent retention, and 
through masked outcome assessment. The external validity 
was maximised by the relatively long follow-up (24 months), 
and good adherence rates in both treatment groups.
The study had several limitations. The sample consisted 
of a group of people at high risk of depressive relapse or 
recurrence,42 currently taking antidepressants, and who 
were open both to considering a group-based psychosocial 
treatment and to discontinuing or continuing 
antidepressant medication. This characteristic is both 
a strength and limitation of the study. The fi ndings 
are therefore only generalisable to the subgroup of 
individuals in equipoise about type of preventive treatment. 
Moreover, our recruitment strategy consisted of searching 
primary care databases and inviting patients who were 
currently taking maintenance antidepressants rather than 
recruiting patients who were discussing their options for 
preventing relapse or recurrence with their GP.
The design included neither a usual care nor an attention 
control group. The absence of an attention control group 
means any eff ects of MBCT cannot be inferred to be 
specifi c to MBCT; ongoing studies of mechanisms of 
action in MBCT from our group will address this question. 
Finally, the pragmatic nature of the trial means that a 
subgroup of patients in both groups did not comply with 
the study invitation to discontinue antidepressant 
medication. This charac teristic is both a strength 
(pragmatism and generalisability) and limitation (the 
antidepressant medication was not fully controlled).
In a large rigorous, yet pragmatic randomised trial we 
have shown that MBCT-TS is not superior to maintenance 
antidepressants over 2 years of follow-up for patients with 
recurrent depression. Benchmarked against epidemio-
logical data, both treatments were associated with enduring 
positive outcomes in terms of relapse or recurrence, 
residual depressive symptoms, and quality of life. This 
study, combined with previous studies, provides important 
evidence that MBCT-TS might confer ongoing protection 
for patients who would like an alternative to maintenance 
antidepressant medication. The results further suggest that 
psychosocial treatments such as MBCT and CBT7,40,43 off er 
added value for patients who need them most (ie, those at 
highest risk of depressive relapse or recurrence). However, 
studies have tended to operationalise risk in somewhat 
diff erent ways (such as early adversity, unstable remission, 
more previous episodes, early age of onset) and although 
these risk factors overlap, future research should examine 
how and through what mechanism risk is conferred and 
resilience learned. In the interim, the implication is that for 
patients at low risk, treatments such as psycho-education or 
maintenance antidepressants, which require less patient 
commitment and cost, might be indicated, whereas for 
patients at highest risk, more intensive treatments such as 
MBCT could be indicated. This implication has substantial 
potential to improve prevention by maximising the delivery 
of treatments through stratifi ed approaches, which also 
have the potential to improve patient choice.
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Panel: Research in context
Systematic review
A 2011 meta-analysis identifi ed two small trials comparing the eff ectiveness of 
mindfulness-based cognitive therapy with support to taper or discontinue antidepressant 
medication (MBCT-TS) with maintenance antidepressants in prevention of relapse or 
recurrence, following up participants for 60 weeks.6 We did some searches of electronic 
databases (Embase, PubMed, PsycINFO, Web of Science, Scopus, and the Cochrane 
Controlled Trials Register) from the fi rst available year to Nov 22, 2014, using keywords 
(mindfulness-based cognitive therapy) OR (mindfulness based cognitive therapy) OR 
(MBCT) AND depress*). No language or other limitations were imposed. We screened 
abstracts to retrieve full-text articles for assessment of eligibility. We also checked reference 
lists of relevant studies and reviews for additional references to potentially relevant studies. 
This search identifi ed no further published trials. The combined relative risk ratio of MBCT-
TS versus maintenance antidepressants was 0·80 (95% CI 0·60–1·08, z=1·45, p=0·15), 
corresponding to a non-signifi cant risk reduction of 20%. We extended these fi ndings with 
a large pragmatic superiority trial of MBCT-TS compared with maintenance antidepressants 
for people with a history of three or more previous episodes of depression. The primary 
outcome was relapse or recurrence over 2 years of follow-up. MBCT-TS was not superior to 
maintenance antidepressant medication in terms of time to depressive relapse or 
recurrence over the 24 months (hazard ratio 0·89, 0·67–1·18). We pooled our trial data with 
the equivalent MBCT-TS and maintenance antidepressant medication groups of the 
previous two randomised controlled trials (n=12310 and n=5439), and used the equivalent 
60-week follow-up point available across all three studies. The combined relative risk ratio 
of MBCT-TS versus maintenance antidepressants was 0·76 (95% CI 0·59–0·98), a risk 
reduction of 24%. There was no evidence of statistical heterogeneity.
Interpretation
We found no evidence that MBCT-TS is superior to maintenance antidepressant treatment 
for the prevention of depressive relapse. However, when considered in the context of the 
totality of randomised controlled data, we found evidence from this trial to support 
MBCT-TS as an alternative to maintenance antidepressants for prevention of depressive 
relapse or recurrence at similar costs. It allows such individuals to stay well and maintain 
good quality of life. In patients who report childhood abuse, MBCT-TS might confer greater 
benefi t than maintenance antidepressants in prevention of depressive relapse or recurrence.
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